


Supplementary Fig. S1. Comparison of poor outcome-free survival rates according to the number of MetS components in AAV patients with MetS.

No significant differences in the cumulative relapse-free, ESRD-free, CVA-free, and ACS-free survival rates among AAV patients with 3, 4, and 5 MetS components were found.


MetS: metabolic syndrome; AAV: antineutrophil cytoplasmic antibody-associated vasculitis; ESRD: end-stage renal disease; CVA: cerebrovascular accident; ACS: acute coronary syndrome.



Supplementary Fig. S2. Comparison of survival rates among IGF or T2DM (+), only T2DM (+) and only IFG (+) in AAV patients with MetS.

Patients with only IFG exhibited a significantly lower cumulative patients' survival rate than those without.

IFG: impaired fasting glucose; T2DM: type 2 diabetes mellitus; AAV: antineutrophil cytoplasmic antibody-associated vasculitis; MetS: metabolic syndrome.



Supplementary Fig. S3. Comparison of survival rates according to the number of MetS components in MPA and GPA patients with MetS.

When only the 49 MPA patients with MetS were analysed, the cumulative survival rates were significantly associated with the number of MetS components. MetS: metabolic syndrome; AAV: antineutrophil cytoplasmic antibody-associated vasculitis; MPA: microscopic polyangiitis; GPA: granulomatosis with polyangiitis.